Recent, large-scale analysis reported in Lancet Psychiatry found no rigorous evidence that cannabis or medical cannabinoids effectively treat anxiety, depression, or PTSD. The source article summarizes that the available data do not support therapeutic claims for these psychiatric conditions and that the literature, when examined broadly, does not demonstrate clear benefit.
The authors of the DentistryIQ piece state plainly that marijuana should not be prescribed for people with these mental health diagnoses. That position is based on the conclusion from the referenced analysis that clinical benefit has not been established.
The Lancet Psychiatry review that the article cites represents a sweeping look at the evidence base for medical cannabis in common psychiatric disorders. According to the article, this synthesis is significant because it challenges widely held perceptions that cannabis reliably alleviates symptoms of anxiety, depression, or posttraumatic stress.
For clinicians and care teams, such evidence syntheses inform risk–benefit assessments, prescribing decisions, and patient counseling. The DentistryIQ article uses the Lancet Psychiatry findings to question the therapeutic role of cannabis in mental health care and to emphasize the need for caution.
Although the original piece appears in a dental clinical forum, the implications extend to any clinician who evaluates patients using or requesting cannabis products. The article highlights that dental professionals should be aware that current high-level evidence does not support cannabis as an effective treatment for anxiety, depression, or PTSD.
Because dental teams frequently encounter patients with comorbid medical and psychiatric conditions, awareness of the evidence and of potential harms is important for risk assessment, perioperative planning, and patient education. The article frames this information as relevant to the dental office, where providers may need to discuss medication use, including cannabis, with patients.
The article reports that the Lancet Psychiatry analysis found that marijuana products can worsen mental health in some patients and are associated with significant adverse events. It notes that use of cannabis may lead to negative outcomes rather than therapeutic effects for those with anxiety, depression, or PTSD.
The source also emphasizes that reliance on cannabis can delay access to proven medical treatments. Delayed or substituted treatment may allow underlying psychiatric conditions to persist or progress, with attendant functional and clinical consequences.
A core concern raised in the article is that cannabis may temporarily blunt or disguise symptoms, which can give the false impression of improvement. By masking the clinical picture, cannabis use may complicate accurate diagnosis and management and can divert patients from evidence-based therapies.
The DentistryIQ authors caution that masking symptoms risks ignoring underlying pathology and thereby postponing interventions with established benefit. This is presented as a practical clinical risk when patients or clinicians substitute cannabis for standard treatments.
The DentistryIQ piece concludes that, based on the Lancet Psychiatry review, cannabis should not be prescribed for anxiety, depression, or PTSD. It stresses that current rigorous evidence does not demonstrate benefit and that cannabis use may produce harm, delay effective therapy, and produce adverse events.
The article urges clinicians to weigh these findings when considering cannabis in the context of mental health management and to prioritize evidence-based treatments. It frames the topic within the Medical History Mysteries series to highlight evolving research and to encourage clinician awareness.
This article was authored by Pamela Maragliano, DMD, chief editor of Dental Economics, and Tom Viola, RPh, CCP, a board-certified pharmacist and clinical educator. The piece first appeared in the Clinical Insights newsletter published by the Endeavor Business Media Dental Group and is part of the Medical History Mysteries video series. The source credits a Lancet Psychiatry analysis for the evidence discussed.
Editor’s note: The original article appeared in Clinical Insights, a publication of the Endeavor Business Media Dental Group. Details beyond those reported in the source — including full methodology, quantitative outcomes, or additional study citations — were not provided in the DentistryIQ article.